My name is Shivali Chag and I am a Scientific Project Manager at University of California, San Francisco (UCSF). My expertise lies in the field of infectious diseases, vaccine development & scientific project management. I have authored few peer- reviewed publications.

In my current role, as a Scientific Project Manager at QBI, UCSF, I am managing QBI’s infectious disease portfolio. I am a trained vaccine researcher with broad understanding of optimization and cGMP manufacturing of both upstream and downstream process for Phase I recombinant protein vaccine candidates along with associated in-process analytical assays. Prior to coming to QBI, I worked as a Clinical Trial Manager for a novel lentivirus mediated gene therapy clinical trial for treatment of Artemis Deficient SCID at UCSF. In that role, I helped the lab of Dr. Jennifer Puck in taking their preclinical findings from the lab bench to the clinic by submitting an Investigational New Drug (IND) application, securing FDA approval & overseeing all operations of the trial from study start up to follow up of patients & working closely with the clinical team.

Throughout my scientific career in academia over 12 years, I have been passionate about clinical research & project management, focusing on enabling project teams to efficiently and effectively gather and analyze data, meet timelines and make decisions.

Wang B, Vartak R, Zaltsman Y, Naing ZZC, Hennick KM, Polacco BJ, Bashir A, Eckhardt M, Bouhaddou M, Xu J, Sun N, Lasser MC, Zhou Y, McKetney J, Guiley KZ, Chan U, Kaye JA, Chadha N, Cakir M, Gordon M, Khare P, Drake S, Drury V, Burke DF, Gonzalez S, Alkhairy S, Thomas R, Lam S, Morris M, Bader E, Seyler M, Baum T, Krasnoff R, Wang S, Pham P, Arbalaez J, Pratt D, Chag S, Mahmood N, Rolland T, Bourgeron T, Finkbeiner S, Swaney DL, Bandyopadhay S, Ideker T, Beltrao P, Willsey HR, Obernier K, Nowakowski TJ, Hüttenhain R, State MW, Willsey AJ, Krogan NJ. A foundational atlas of autism protein interactions reveals molecular convergence. bioRxiv [Preprint]. 2024 Feb 8:2023.12.03.569805. doi: 10.1101/2023.12.03.569805. PMID: 38076945; PMCID: PMC10705567.

Cowan MJ, Yu J, Facchino J, Fraser-Browne C, Sanford U, Kawahara M, Dara J, Long-Boyle J, Oh J, Chan W, Chag S, Broderick L, Chellapandian D, Decaluwe H, Golski C, Hu D, Kuo CY, Miller HK, Petrovic A, Currier R, Hilton JF, Punwani D, Dvorak CC, Malech HL, McIvor RS, Puck JM. Lentiviral Gene Therapy for Artemis-Deficient SCID. N Engl J Med. 2022 Dec 22;387(25):2344-2355. doi: 10.1056/NEJMoa2206575. PMID: 36546626; PMCID: PMC9884487.

Chen WH, Chag SM, Poongavanam MV, Biter AB, Ewere EA, Rezende W, Seid CA, Hudspeth EM, Pollet J, McAtee CP, Strych U, Bottazzi ME, Hotez PJ. Optimization of the Production Process and Characterization of the Yeast-Expressed SARS-CoV Recombinant Receptor-Binding Domain (RBD219-N1), a SARS Vaccine Candidate. J Pharm Sci. 2017 Aug;106(8):1961-1970. doi: 10.1016/j.xphs.2017.04.037. Epub 2017 Apr 26. PMID: 28456726; PMCID: PMC5612335.

Chen WH, Du L, Chag SM, Ma C, Tricoche N, Tao X, Seid CA, Hudspeth EM, Lustigman S, Tseng CT, Bottazzi ME, Hotez PJ, Zhan B, Jiang S. Yeast-expressed recombinant protein of the receptor-binding domain in SARS-CoV spike protein with deglycosylated forms as a SARS vaccine candidate. Hum Vaccin Immunother. 2014;10(3):648-58. doi: 10.4161/hv.27464. Epub 2013 Dec 30. PMID: 24355931; PMCID: PMC4130269.